Glucose-dependent insulinotropic polypeptide augmentation of insulin
Finding the right dose is a matter of balancing stronger effects against tolerability
Ltd., Ipsen SA, Johnson & Johnson, Merck & Co
Quick Stats for Obesity GLP-1 Market Obesity GLP-1 Market Value (2025): USD 8,169 million Obesity GLP-1 Market Forecast Value (2035): USD 65,364 million Obesity GLP-1 Market Forecast CAGR: 23.1% Leading Molecule Class in Obesity GLP-1 Market: Semaglutide (58.0%) Key Growth Regions in Obesity GLP-1 Market: North America, Europe, and East Asia Top Key Players in Obesity GLP-1 Market: Novo Nordisk, Eli Lilly, and emerging manufacturers Between 2025 and 2030, the obesity GLP-1 market is projected to expand from USD 8169.0 million to USD 39,528 million, resulting in a value increase of USD 31359.0 million, which represents 54.8% of the total forecast growth for the decade
Call or Text: 312.312.7873 Book Appointment Online: A consultation helps determine whether prescription GLP-1 therapy is right for you and explains the difference between prescription GLP-1 vs compounded weight loss injections in detail
